ALX Oncology Holdings Inc (ALXO)
1.515
+0.02
(+1.68%)
USD |
NASDAQ |
Nov 05, 16:00
1.53
+0.02
(+0.99%)
After-Hours: 18:43
ALX Oncology Holdings Enterprise Value: -68.47M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | -68.47M |
| November 01, 2024 | -70.58M |
| October 31, 2024 | -71.63M |
| October 30, 2024 | -74.27M |
| October 29, 2024 | -73.21M |
| October 28, 2024 | -70.05M |
| October 25, 2024 | -69.53M |
| October 24, 2024 | -70.32M |
| October 23, 2024 | -59.52M |
| October 22, 2024 | -67.95M |
| October 21, 2024 | -67.95M |
| October 18, 2024 | -69.00M |
| October 17, 2024 | -67.42M |
| October 16, 2024 | -64.79M |
| October 15, 2024 | -64.79M |
| October 14, 2024 | -65.31M |
| October 11, 2024 | -65.84M |
| October 10, 2024 | -71.11M |
| October 09, 2024 | -61.63M |
| October 08, 2024 | -60.05M |
| October 07, 2024 | -63.21M |
| October 04, 2024 | -58.47M |
| October 03, 2024 | -56.36M |
| October 02, 2024 | -50.56M |
| October 01, 2024 | -48.98M |
| Date | Value |
|---|---|
| September 30, 2024 | -51.09M |
| September 27, 2024 | -43.19M |
| September 26, 2024 | -48.46M |
| September 25, 2024 | -51.62M |
| September 24, 2024 | -44.24M |
| September 23, 2024 | -42.14M |
| September 20, 2024 | -37.92M |
| September 19, 2024 | -32.66M |
| September 18, 2024 | -34.24M |
| September 17, 2024 | -32.13M |
| September 16, 2024 | -32.13M |
| September 13, 2024 | -30.02M |
| September 12, 2024 | -34.24M |
| September 11, 2024 | -32.13M |
| September 10, 2024 | -33.18M |
| September 09, 2024 | -36.34M |
| September 06, 2024 | -46.35M |
| September 05, 2024 | -42.14M |
| September 04, 2024 | -38.45M |
| September 03, 2024 | -34.24M |
| August 30, 2024 | -24.76M |
| August 29, 2024 | -25.81M |
| August 28, 2024 | -23.70M |
| August 27, 2024 | -15.80M |
| August 26, 2024 | -11.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-76.99M
Minimum
Jun 16 2022
3.912B
Maximum
Dec 10 2020
802.71M
Average
307.79M
Median
Nov 20 2023
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 12.24B |
| Neurocrine Biosciences Inc | 10.98B |
| Eton Pharmaceuticals Inc | 202.70M |
| Verve Therapeutics Inc | -64.82M |
| Immuneering Corp | -4.573M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -39.40M |
| Total Expenses (Quarterly) | 41.52M |
| EPS Diluted (Quarterly) | -0.76 |
| Earnings Yield | -239.6% |
| Normalized Earnings Yield | -69.44 |